# Not all antibody tests are created equal

## High quality, extensive reach and targeting the right protein are all essential to ensure we effectively manage the threat of COVID-19

### The SARS-CoV-2 Total Assay[1] is a highly sensitive and accurate antibody test

A total antibody test enables a **clearer clinical picture** over longer period of time.






### Delivering long-term value as we look toward immunity and vaccination

The test detects antibodies to a key protein on the surface of the virus – a **spike protein**, which binds the virus to cells via a distinct human receptor (ACE2) found in lungs, heart, and multiple organs.




Studies indicate that certain (neutralizing) antibodies to the spike protein can **disarm SARS-CoV-2**, presumably by interfering with the ability of the virus to bind, penetrate and infect human cells.




**What is sensitivity and specificity?**
A highly sensitive test should capture nearly all true positive results.
A highly specific test should avoid nearly all false positive results.

**100%** sensitivity[2]

**99.8%** specificity[3]



Total antibody blood tests, which run on laboratory analyzers, detect antibodies to SARS-CoV-2 (including IgG and IgM), that are used to identify those with an immune response that indicates recent infection or prior exposure.

## Rapid

**Identify SARS-CoV-2 antibodies in as little as 10 minutes.[5]**

### Reaching millions of patients

**~20,000**

**analyzers worldwide[4] with the largest installed base in the U.S.**

**50M/month**

**Production according to market demand as pandemic evolves**

1. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting he presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.
2. For samples collected ≥14 days after positive PCR results.
3. Based on results for the ADVIA Centaur COV2T assay.
4. Installed base of ADVIA Centaur XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica Solution, Dimension Vista and Dimension EXL analyzers.
5. Dependent on text mix and configuration using Atellica Solution.

HOOD05162003093528

SIEMENS Healthineers